Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Tuesday
Mar132012

Aastrom (ASTM): Reports the Quarter, JMP Makes Positive Comments

Aastrom (ASTM): Reports the Quarter its great to have the cash but...

Highlights As follows:

  1. The company ended 2011 with cash of $5.5MM which, together with $40MM raised last week should fund current operations through mid 2013.
  2. The Phase III trial for ixmyelocel-T in critical limb ischemia (CLI) has begun. Enrollment will be monitores (this is a large trial, how long will it take ?).
  3. Aastrom is planning to move ahead with a phase IIb trial in dilated cardiomyopathy (DCM) by this summer. Reesults from the Phase 1b trial are expected this quarter.

Daily Dose Conclusion: Its great that Aastrom is financed but we convertible debt is atypical for Biotech's and raises the importance of the CLI trial. We believe the trial is highly powered and if all goes well will show good results but as mentioned previously, the "B" in binary just got a bit Bigger.  CLI is an unmet medical need. Aastrom does appear to have the jump on the field (versus Pluristem (PSTI) and Aldagen / Cytomedic

PrintView Printer Friendly Version

EmailEmail Article to Friend

References (3)

References allow you to track sources for this article, as well as articles that were written in response to this article.
  • Response
    Daily Dose Equities - Wall Street Analysis for Biotech Research - Daily Dose Newsroom - Aastrom (ASTM): Reports the Quarter, JMP Makes Positive Comments
  • Response
    855 You will require 9 darkish strips and 8 white strips to the weave. The only frequent that continues to be inside our kid's lives, calendar year in, yr out, louis vuitton don for sale looks being their basically phobic distaste for strolling.
  • Response
    Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Aastrom (ASTM): Reports the Quarter, JMP Makes Positive Comments

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« CytRx ($CYTR): Oncology Value Play ? Cowen thinks so... | Main | Stem ($STEM) Reports the Q4: $13 Million left in the bank »